The chief medical officer at Edgewise discussed long-term MESA data showing sustained functional stabilization with sevasemten in Becker muscular dystrophy and its potential as a disease-modifying therapy.
Joanne Donovan, MD, PhD
Advertisement
Articles by Joanne Donovan, MD, PhD
The chief medical officer at Edgewise Therapeutics gave an overview of the mechanism of EDG-5506, an agent in development for Becker muscular dystrophy, and its early promising clinical results to date. [WATCH TIME: 6 minutes]
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Roche Unveils PrevenTRON, a Phase 3 Prevention Trial of Trontinemab in Cognitively Unimpaired Individuals at High Risk of Alzheimer Decline
2
Alzheimer's Association Launches PROTECT-Cog Combination Prevention Trial
3
FDA Accepts BLA for Z-Rostudirsen in DMD, Sets January PDUFA Date
4
Contextualizing Lecanemab’s New Subcutaneous Weekly Starting Dose
5